Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab in sporadic inclusion body myositis (RESILIENT)
NCT01925209Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2013
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of bimagrumab in sporadic inclusion body myositis (sIBM), sponsored by Novartis. Started Sep 2013; status: completed.
02
Drugs
bimagrumab
03
Conditions
sporadic inclusion body myositis (sIBM)
Beyond the preview
Go deeper on NCT01925209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01925209.